Literature DB >> 20422156

Flibanserin, a drug intended for treatment of hypoactive sexual desire disorder in pre-menopausal women, affects spontaneous motor activity and brain neurochemistry in female rats.

Boris Ferger1, Makoto Shimasaki, Angelo Ceci, Carina Ittrich, Kelly A Allers, Bernd Sommer.   

Abstract

Flibanserin, a 5-HT(1A) receptor agonist and 5-HT(2A) receptor antagonist, is being developed for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women. Here, we investigated the effects of acute administration of flibanserin (15 and 45 mg/kg, p.o.) and the selective 5-HT(1A) receptor agonist (+)-8-OH-DPAT (1 mg/kg, i.p.) on neurotransmitter levels in brain areas of female rats. Specifically, levels of dopamine (DA) and serotonin (5-HT) and neurotransmitter metabolites were examined in prefrontal cortex (PFC), nucleus accumbens, hypothalamus and brain stem using high performance liquid chromatography coupled to electrochemical detection. In addition, spontaneous motor activity was determined in an automated motor activity system. Flibanserin (45 mg/kg) but not (+)-8-OH-DPAT significantly reduced motor activity, when compared to vehicle controls. Specifically, the DA turnover was significantly increased (279%) in the PFC after flibanserin treatment but less pronounced (159%) after 8-OH-DPAT administration. Serotonin tissue levels were not altered in any of the investigated brain regions upon flibanserin treatment. However, flibanserin produced a significant decrease of the major serotonin metabolite 5-hydroxyindoleacetic acid and 5-HT turnover in the PFC, nucleus accumbens, hypothalamus and brain stem similar to (+)-8-OH-DPAT. In conclusion, the present study indicates that flibanserin is able to modulate dopaminergic and serotonergic activity in distinct brain areas. The observed effects in the PFC on dopaminergic markers are different from those induced by (+)-8-OH-DPAT and may contribute to its therapeutic efficacy in HSDD. The effects of flibanserin on spontaneous motor behaviour are in agreement with its receptor profile and underscore that flibanserin is devoid of any locomotor hyperactivity inducing properties.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20422156     DOI: 10.1007/s00210-010-0515-8

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  19 in total

1.  Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat.

Authors:  M Hajós; E Hajós-Korcsok; T Sharp
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

2.  Sexual problems and distress in United States women: prevalence and correlates.

Authors:  Jan L Shifren; Brigitta U Monz; Patricia A Russo; Anthony Segreti; Catherine B Johannes
Journal:  Obstet Gynecol       Date:  2008-11       Impact factor: 7.661

3.  Effect of flibanserin (BIMT 17), fluoxetine, 8-OH-DPAT and buspirone on serotonin synthesis in rat brain.

Authors:  A Brambilla; A Baschirotto; N Grippa; F Borsini
Journal:  Eur Neuropsychopharmacol       Date:  1999-12       Impact factor: 4.600

4.  The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat.

Authors:  C J Schmidt; G M Fadayel
Journal:  Eur J Pharmacol       Date:  1995-02-06       Impact factor: 4.432

5.  Electrophysiological examination of the effects of sustained flibanserin administration on serotonin receptors in rat brain.

Authors:  L E Rueter; P Blier
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

6.  Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo.

Authors:  S Prisco; S Pagannone; E Esposito
Journal:  J Pharmacol Exp Ther       Date:  1994-10       Impact factor: 4.030

7.  Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study.

Authors:  C R Ashby; E Edwards; R Y Wang
Journal:  Synapse       Date:  1994-07       Impact factor: 2.562

8.  Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors.

Authors:  Roberto William Invernizzi; Giuseppina Sacchetti; Stefania Parini; Sabrina Acconcia; Rosario Samanin
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

9.  BIMT 17, a 5-HT1A receptor agonist/5-HT2A receptor antagonist, directly activates postsynaptic 5-HT inhibitory responses in the rat cerebral cortex.

Authors:  F Borsini; A Ceci; G Bietti; A Donetti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-09       Impact factor: 3.000

10.  In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre- and postsynaptic 5-HT1A receptors in the rat brain.

Authors:  L E Rueter; C de Montigny; P Blier
Journal:  Synapse       Date:  1998-08       Impact factor: 2.562

View more
  6 in total

1.  Flibanserin and 8-OH-DPAT implicate serotonin in association between female marmoset monkey sexual behavior and changes in pair-bond quality.

Authors:  Yves Aubert; Morgan L Gustison; Lindsey A Gardner; Michael A Bohl; Jason R Lange; Kelly A Allers; Bernd Sommer; Nicole A Datson; David H Abbott
Journal:  J Sex Med       Date:  2012-02-03       Impact factor: 3.802

2.  Population pharmacokinetic/pharmacodynamic model for the sedative effects of flibanserin in healthy volunteers.

Authors:  Iñaki F Trocóniz; Katja Boland; Alexander Staab
Journal:  Pharm Res       Date:  2012-01-05       Impact factor: 4.200

Review 3.  Flibanserin: First Global Approval.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

4.  Preclinical Abuse Potential Assessment of Flibanserin: Effects on Intracranial Self-Stimulation in Female and Male Rats.

Authors:  Matthew F Lazenka; Bruce E Blough; S Stevens Negus
Journal:  J Sex Med       Date:  2016-01-28       Impact factor: 3.802

Review 5.  Cell Therapy Products in Alzheimer Disease.

Authors:  Hyeon Jin Song; Tae-Hee Kim; Hae-Hyeog Lee; Jun-Mo Kim; Yoo Jin Park; Arum Lee; Soo Ah Kim; Hye Ji Choi
Journal:  J Menopausal Med       Date:  2017-04-28

6.  Survey of the Literature December 2015.

Authors:  Theodore R Saitz; Johanna L Hannan; Lesley Marson; Michael Krychman; Rose Hartzell-Cushanick; Sophie Bergeron; John Dean
Journal:  Sex Med       Date:  2015-12-28       Impact factor: 2.491

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.